The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia

被引:77
|
作者
Eisfeld, A-K [1 ]
Mrozek, K. [1 ]
Kohlschmidt, J. [1 ,2 ]
Nicolet, D. [1 ,2 ]
Orwick, S. [3 ]
Walker, C. J. [1 ]
Kroll, K. W. [3 ]
Blachly, J. S. [3 ]
Carroll, A. J. [4 ]
Kolitz, J. E. [5 ]
Powell, B. L. [6 ]
Wang, E. S. [7 ]
Stone, R. M. [8 ]
de la Chapelle, A. [1 ]
Byrd, J. C. [3 ]
Bloomfield, C. D. [1 ]
机构
[1] Ohio State Univ, Ctr Comprehens Canc, 460 West 12th Ave,Room 850, Columbus, OH 43210 USA
[2] Mayo Clin, Alliance Stat & Data Ctr, Rochester, MN USA
[3] Ohio State Univ, Dept Internal Med, Ctr Comprehens Canc, Div Hematol, Columbus, OH 43210 USA
[4] Univ Alabama Birmingham, Dept Genet, Birmingham, AL USA
[5] Hofstra North Shore Long Isl Jewish Sch Med, Monter Canc Ctr, Lake Success, NY USA
[6] Wake Forest Univ, Comprehens Canc Ctr, Winston Salem, NC 27109 USA
[7] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA
[8] Dana Farber Partners CancerCare, Dept Med Oncol, Boston, MA USA
基金
美国国家卫生研究院;
关键词
INTENSIVE POSTREMISSION CHEMOTHERAPY; COMPLEX ABERRANT KARYOTYPE; COLONY-STIMULATING FACTOR; AGE; 60; YEARS; GROUP-B; PROGNOSTIC-SIGNIFICANCE; MONOSOMAL KARYOTYPE; DOSE CYTARABINE; CANCER GENOMICS; YOUNGER ADULTS;
D O I
10.1038/leu.2017.86
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recurrent chromosomal abnormalities and gene mutations detected at the time of diagnosis of acute myeloid leukemia (AML) are associated with particular disease features, treatment response and survival of AML patients, and are used to denote specific disease entities in the World Health Organization classification of myeloid neoplasms and acute leukemia. However, large studies that integrate cytogenetic and comprehensive mutational information are scarce. We created a comprehensive oncoprint of mutations associated with recurrent cytogenetic findings by combining the information on mutational patterns of 80 cancer- and leukemia-associated genes with cytogenetic findings in 1603 adult patients with de novo AML. We show unique differences in the mutational profiles among major cytogenetic subsets, identify novel associations between recurrent cytogenetic abnormalities and both specific gene mutations and gene functional groups, and reveal differences in cytogenetic and mutational features between patients younger than 60 years and those aged 60 years or older. The identified associations between cytogenetic and molecular genetic data may help guide mutation testing in AML, and result in more focused application of targeted therapy in patients with de novo AML.
引用
收藏
页码:2211 / 2218
页数:8
相关论文
共 50 条
  • [31] Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies
    Eisfeld, Ann-Kathrin
    Kohlschmidt, Jessica
    Mrozek, Krzysztof
    Blachly, James S.
    Walker, Christopher J.
    Nicolet, Deedra
    Orwick, Shelley
    Maharry, Sophia E.
    Carroll, Andrew J.
    Stone, Richard M.
    de la Chapelle, Albert
    Wang, Eunice S.
    Kolitz, Jonathan E.
    Powell, Bayard L.
    Byrd, John C.
    Bloomfield, Clara D.
    LEUKEMIA, 2018, 32 (06) : 1338 - 1348
  • [32] Additional chromosomal abnormalities in core-binding factor acute myeloid leukemia
    Hsiao, H. H.
    Liu, Y. C.
    Wang, H. C.
    Tsai, Y. F.
    Wu, C. H.
    Cho, S. F.
    Hsu, J. F.
    Huang, C. T.
    Hsiao, S. Y.
    Lee, C. P.
    Chang, C. S.
    Lin, S. F.
    Liu, T. C.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (04) : 17028 - 17033
  • [33] The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication
    Renneville, Aline
    Boissel, Nicolas
    Gachard, Nathalie
    Naguib, Dina
    Bastard, Christian
    de Botton, Stephane
    Nibourel, Olivier
    Pautas, Cecile
    Reman, Oumedaly
    Thomas, Xavier
    Gardin, Claude
    Terre, Christine
    Castaigne, Sylvie
    Preudhomme, Claude
    Dombret, Herve
    BLOOD, 2009, 113 (21) : 5090 - 5093
  • [34] Monosomal karyotype is not a predictor of dismal outcome in childhood de novo acute myeloid leukemia
    Lee, Na Hee
    Choi, Young Bae
    Yi, Eun-Sang
    Lee, Soo Hyun
    Kim, Hee-Jin
    Lee, Ji Won
    Sung, Ki Woong
    Koo, Hong Hoe
    Yoo, Keon Hee
    LEUKEMIA RESEARCH, 2016, 50 : 57 - 62
  • [35] High EVI1 Expression Predicts Poor Outcomes in Adult Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk Receiving Chemotherapy
    Qin, Ya-Zhen
    Zhao, Ting
    Zhu, Hong-Hu
    Wang, Jing
    Jia, Jin-Song
    Lai, Yue-Yun
    Zhao, Xiao-Su
    Shi, Hong-Xia
    Liu, Yan-Rong
    Jiang, Hao
    Huang, Xiao-Jun
    Jiang, Qian
    MEDICAL SCIENCE MONITOR, 2018, 24 : 758 - 767
  • [36] Expression analysis of BECN1 in acute myeloid leukemia: association with distinct cytogenetic and molecular abnormalities
    Zare-Abdollahi, D.
    Safari, S.
    Movafagh, A.
    Ghadiani, M.
    Tabarraee, M.
    Riazi-Isfahani, S.
    Gorji, S.
    Keyvan, L.
    Gachkar, L.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2016, 38 (02) : 125 - 132
  • [37] Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission
    Vasu, Sumithira
    Kohlschmidt, Jessica
    Mrozek, Krzysztof
    Eisfeld, Ann-Kathrin
    Nicolet, Deedra
    Sterling, Lisa J.
    Becker, Heiko
    Metzeler, Klaus H.
    Papaioannou, Dimitrios
    Powell, Bayard L.
    Kolitz, Jonathan E.
    Moore, Joseph O.
    Baer, Maria R.
    Roboz, Gail J.
    Stone, Richard M.
    Byrd, John C.
    Carroll, Andrew J.
    Bloomfield, Clara D.
    BLOOD ADVANCES, 2018, 2 (13) : 1645 - 1650
  • [38] Impact of aberrant antigens expression on remission rate after first induction course of chemotherapy in de novo adult acute myeloid leukemia
    Hussein, Ghaith Abdulkarim
    Jawad, Ali Mohammed
    IRAQI JOURNAL OF HEMATOLOGY, 2021, 10 (02) : 118 - 122
  • [39] De novo adult acute myeloid leukemia with two new mutations in juxtatransmembrane domain of the FLT3 gene: a case report
    Alarbeed, Ismael F.
    Wafa, Abdulsamad
    Moassass, Faten
    Al-Halabi, Bassel
    Al-Achkar, Walid
    Liehr, Thomas
    Aboukhamis, Imad
    JOURNAL OF MEDICAL CASE REPORTS, 2021, 15 (01)
  • [40] Redefining Remission Induction Chemotherapy Ineligibility by Early Mortality in De Novo Acute Myeloid Leukemia
    Li, You-Cheng
    Shih, Yu-Hsuan
    Chen, Tsung-Chih
    Gau, Jyh-Pyng
    Su, Yu-Chen
    Chen, Mei-Hui
    Hsu, Chiann-Yi
    Liao, Cai-Sian
    Teng, Chieh-Lin Jerry
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (24)